(19)
(11) EP 4 680 639 A1

(12)

(43) Date of publication:
21.01.2026 Bulletin 2026/04

(21) Application number: 24712960.4

(22) Date of filing: 12.03.2024
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/505; A61K 2039/507; A61K 2039/545; A61P 35/00; C07K 16/2818; C07K 16/2863; C07K 2317/21; C07K 2317/24; C07K 2317/31; C07K 2317/76; C07K 2317/73
(86) International application number:
PCT/IB2024/052394
(87) International publication number:
WO 2024/189544 (19.09.2024 Gazette 2024/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 13.03.2023 US 202363451781 P
17.04.2023 US 202363459857 P

(71) Applicant: Janssen Biotech, Inc.
Horsham, PA 19044 (US)

(72) Inventors:
  • CURTIN, Joshua
    Spring House, Pennsylvania 19477 (US)
  • BAIG, Mahadi
    Spring House, Pennsylvania 19477 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) COMBINATION THERAPIES WITH BI-SPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND ANTI-PD-1 ANTIBODIES